| Name | U-104 |
| Description | U-104 (NSC-213841) is an effective carbonic anhydrase (CA) inhibitor for CA IX( Ki=45.1 nM) and CA XII(Ki=4.5 nM). |
| Kinase Assay | Kinase assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
| In vitro | UNC1215 increased cell mobility and point mutations of the GFP-L3MBTL3 fusion protein, interfered with the Kme-binding function of the GFP-L3MBTL3 phenotypic mimic, and affected the localization of UNC1215.UNC1215 (30 μM) did not affect the tandem Tudor domain of UHRF1, the chromatin domain of CBX7, and the PHD domain of JARID1A. In MCF7,22RV1 and IMR90 cells, UNC0631 significantly reduced H3K9me2 levels. Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). |
| In vivo | UNC1215 increased cell mobility and point mutations of the GFP-L3MBTL3 fusion protein, interfered with the Kme-binding function of the GFP-L3MBTL3 phenotypic mimic, and affected the localization of UNC1215.UNC1215 (30 μM) did not affect the tandem Tudor domain of UHRF1, the chromatin domain of CBX7, and the PHD domain of JARID1A. In MCF7,22RV1 and IMR90 cells, UNC0631 significantly reduced H3K9me2 levels. Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 242.5 mg/mL (783.98 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.47 mM), Sonication is recommended.
|
| Keywords | U-104 | U104 | U 104 | SLC-0111 | SLC0111 | SLC 0111 | NSC213841 | NSC 213841 | MST104 | MST 104 | LM2-4 | Inhibitor | inhibit | exosome | CAXII | CarbonicAnhydrase | Carbonic anhydrase IX | Carbonic anhydrase II | Carbonic anhydrase I | Carbonic Anhydrase | Carbonate dehydratase | CAIX | CAII | CAI | 4T1 |
| Inhibitors Related | Benzenesulfonamide | Urea | Sodium Dihydrogen Phosphate | Cyclamic acid sodium | Hydrochlorothiazide | Orthanilamide | Zonisamide | Tioxolone | 2-Methoxy-4-propylphenol | pNNP | Fluorometholone Acetate | Acesulfame |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
